Agardh C D, Agardh E, Torffvit O
Department of Internal Medicine, University Hospital, Lund, Sweden.
Diabetes Res Clin Pract. 1997 Mar;35(2-3):113-21. doi: 10.1016/s0168-8227(97)01386-7.
The aim of the present study was to examine mean HbA1c and blood pressure levels during a 5 year period in 442 type 1 adult diabetic patients in relation to the incidence and progression of retinopathy, nephropathy and to cardiovascular morbidity and mortality. The study showed, that in patients under routine care at a diabetic unit with four visits to the out-patient clinic per year, the intraindividual coefficient of variation for HbA1c values was 11 +/- 4% (mean +/- S.D.), and 7 +/- 3 and 8 +/- 2% for systolic and diastolic blood pressure, respectively. In 121 patients without retinopathy at entry, the 5 year incidence of any retinopathy was 47% (n = 57). Patients who developed retinopathy had higher mean HbA1c levels (P < 0.01), as well as mean systolic (P < 0.01) and diastolic (P < 0.05) blood pressure levels. In 123 patients with background retinopathy at entry, progression to severe retinopathy, i.e. clinically significant macular oedema, severe non-proliferative or proliferative retinopathy, occurred in 41% (n = 51). In those patients, the degree of metabolic control was worse (P < 0.001), the systolic (P < 0.05) and diastolic (P < 0.01) blood pressure levels were higher. The patients were stratified into four groups according to their urinary albumin concentration at entry: (1) normal albuminuria (< 12.5 mg/l), (2) borderline albuminuria (12.5-30 mg/l), (3) microalbuminuria (31-299 mg/l), i.c. incipient nephropathy and (4) clinical nephropathy (> or = 300 mg/l). An increase of urinary albumin concentration in patients who had normoalbuminuria or borderline albuminuria at entry was associated with mean HbA1c levels (r = 0.24, P < 0.01 and r = 0.27, P < 0.01, respectively). No such association was seen in patients with microalbuminuria or clinical nephropathy at entry. There was no association between the increase of urinary albumin level and mean systolic blood pressure levels in patients who had normoalbuminuria and microalbuminuria at entry. In contrast, there was an association between the increase of urinary albumin level in patients with borderline albuminuria (r = 0.36, P < 0.001), clinical nephropathy (r = 0.26, P < 0.05) and mean systolic blood pressure (P < 0.05). There was no association between the increase of urinary albumin levels and mean diastolic blood pressure in any of the albuminuria groups. As for the incidence of cardiovascular disease, renal insufficiency or death, the duration of diabetes (P < 0.01), urinary albumin concentration at entry (P < 0.001), mean systolic blood pressure (P < 0.05) and treatment with loop diuretics (P < 0.001) were but age, age at onset of diabetes, mean levels of HbA1c and diastolic blood pressure as well as treatment with beta- or Ca-blockers or ACE inhibitors were not related to these end-points. In conclusion, the present study showed that there was an association between the degree of metabolic control and both development and progression of retinopathy and progression of nephropathy of early stages in type 1 diabetic patients treated under routine conditions. Moreover, both the incidence and progression of retinopathy and progression of nephropathy at later stages were also associated with the long-term blood pressure levels. However, HbA1c levels were not associated with morbidity and mortality in cardiovascular disease or development of renal insufficiency.
本研究的目的是在5年期间内,对442例1型成年糖尿病患者的平均糖化血红蛋白(HbA1c)和血压水平进行检测,分析其与视网膜病变、肾病的发生和进展以及心血管疾病发病率和死亡率之间的关系。研究表明,在糖尿病科接受常规治疗、每年门诊就诊4次的患者中,HbA1c值的个体内变异系数为11±4%(均值±标准差),收缩压和舒张压的个体内变异系数分别为7±3%和8±2%。在121例入组时无视网膜病变的患者中,5年时任何视网膜病变的发生率为47%(n = 57)。发生视网膜病变的患者平均HbA1c水平较高(P < 0.01),平均收缩压(P < 0.01)和舒张压(P < 0.05)水平也较高。在123例入组时患有背景性视网膜病变的患者中,进展为严重视网膜病变,即具有临床意义的黄斑水肿、严重非增殖性或增殖性视网膜病变的发生率为41%(n = 51)。在这些患者中,代谢控制程度更差(P < 0.001),收缩压(P < 0.05)和舒张压(P < 0.01)水平更高。根据入组时尿白蛋白浓度将患者分为四组:(1)正常白蛋白尿(< 12.5 mg/l),(2)临界白蛋白尿(12.5 - 30 mg/l),(3)微量白蛋白尿(31 - 299 mg/l),即早期肾病,(4)临床肾病(≥ 300 mg/l)。入组时为正常白蛋白尿或临界白蛋白尿的患者,尿白蛋白浓度升高与平均HbA1c水平相关(r = 0.24,P < 0.01和r = 0.27,P < 0.01)。入组时为微量白蛋白尿或临床肾病的患者未见此类相关性。入组时为正常白蛋白尿和微量白蛋白尿的患者,尿白蛋白水平升高与平均收缩压水平无相关性。相反,临界白蛋白尿(r = 0.36,P < 0.001)、临床肾病(r = 0.26,P < 0.05)患者尿白蛋白水平升高与平均收缩压相关(P < 0.05)。在任何白蛋白尿组中,尿白蛋白水平升高与平均舒张压均无相关性。至于心血管疾病、肾功能不全或死亡的发生率,糖尿病病程(P < 0.01)、入组时尿白蛋白浓度(P < 0.001)、平均收缩压(P < 0.05)和襻利尿剂治疗(P < 0.001)与之相关,但年龄、糖尿病发病年龄、HbA1c平均水平和舒张压以及β受体阻滞剂、钙通道阻滞剂或血管紧张素转换酶抑制剂治疗与这些终点无关。总之,本研究表明,在常规条件下治疗的1型糖尿病患者中,代谢控制程度与视网膜病变的发生和进展以及早期肾病的进展之间存在关联。此外,视网膜病变的发生率和进展以及后期肾病的进展也与长期血压水平相关。然而,HbA1c水平与心血管疾病的发病率和死亡率或肾功能不全的发生无关。